Health
AstraZeneca’s Farxiga prolongs survival in chronic kidney disease trial – Clinical Trials Arena
AstraZeneca has reported positive data from a subgroup analysis from Phase III DAPA-CKD trial of Farxiga (dapagliflozin) in patients with chronic kidney disease…
AstraZeneca has reported positive data from a subgroup analysis from Phase III DAPA-CKD trial of Farxiga (dapagliflozin) in patients with chronic kidney disease (CKD).
The trial data showed that Farxiga helped reduce the composite of worsening of kidney function or risk of cardiovascular (CV) or renal death.
Farxiga is a sodium-glucose co-transporter-2 (SGLT2) inhibitor used for treating patients with insufficiently controlled type-2 diabetes (T2D).
The international, multi-centre, randomised and…
-
Noosa News24 hours agoHomicide investigation launched into stabbing death of 39-year-old Brisbane man at Bowen Hills apartment
-
Noosa News23 hours agoMeasles alert issued across popular south-east attractions
-
General23 hours agoSector warns Coalition’s plan to limit overseas students ‘straight out of Trump’s playbook’
-
Noosa News21 hours agoAll this country music is giving me the honky-tonk blues